Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA CAR-T in Relapsed/Refractory Multiple Myeloma
NCT04637269Phase 1Unknown
- Sponsor
- Xinqiao Hospital
- Start
- Nov 2020
- Primary completion
- Nov 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CBG002 in multiple myeloma (MM), sponsored by Xinqiao Hospital. Primary endpoints: Incidence of dose limiting toxicity at 4 weeks and Incidence and severity of Adverse Events and Serious Adverse Events at 24 months. Status: unknown.
02
Drugs
CBG002
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04637269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04637269.